Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Gastroenteritis

ClinicalTrials.gov lists 5,679 trials for Gastroenteritis or a narrower condition beneath it. Takeda has the most among industry and government lead sponsors, with 96.

MeSH D005759 Digestive System Diseases C06
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 399 Phase 1/2 Phase 1/2 148 Phase 2 Phase 2 714 Phase 2/3 Phase 2/3 103 Phase 3 Phase 3 572 Phase 4 Phase 4 406 Not applicable Not applicable 1,478 Observational Observational 1,848 Phase 1 Phase 1 399 Phase 1/2 Phase 1/2 148 Phase 2 Phase 2 714 Phase 2/3 Phase 2/3 103 Phase 3 Phase 3 572 Phase 4 Phase 4 406 Not applicable Not applicable 1,478 Observational Observational 1,848

Trials per phase

2 more sections with rows

173 of the 5,679 trials are tagged with Gastroenteritis itself; the rest are tagged with a narrower condition beneath it.

Get the Gastroenteritis report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Gastroenteritis trials start? (36)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 12 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Unknown)

Top of scale: 352

1990: 1 trials (Observational 1) 1992: 1 trials (Observational 1) 1993: 1 trials (Phase 3 1) 1994: 1 trials (Phase 3 1) 1995: 4 trials (Observational 2, Not applicable 1, Phase 2/3 1) 1996: 9 trials (Observational 3, Phase 3 2, Phase 2 1, Phase 1 3) 1997: 4 trials (Observational 2, Not applicable 1, Phase 1 1) 1998: 2 trials (Observational 2) 1999: 7 trials (Observational 2, Not applicable 1, Phase 4 1, Phase 3 2, Phase 1 1) 2000: 17 trials (Observational 6, Not applicable 2, Phase 3 4, Phase 2/3 1, Phase 2 3, Phase 1 1) 2001: 26 trials (Observational 6, Not applicable 3, Phase 4 1, Phase 3 5, Phase 2/3 1, Phase 2 4, Phase 1/2 1, Phase 1 5) 2002: 44 trials (Observational 7, Not applicable 2, Phase 4 3, Phase 3 12, Phase 2/3 2, Phase 2 17, Phase 1/2 1) 2003: 56 trials (Observational 11, Not applicable 3, Phase 4 4, Phase 3 17, Phase 2/3 3, Phase 2 16, Phase 1 2) 2004: 74 trials (Observational 15, Not applicable 13, Phase 4 7, Phase 3 22, Phase 2/3 1, Phase 2 9, Phase 1/2 3, Phase 1 4) 2005: 97 trials (Observational 19, Not applicable 7, Phase 4 15, Phase 3 24, Phase 2/3 2, Phase 2 22, Phase 1/2 3, Phase 1 5) 2006: 127 trials (Observational 25, Not applicable 21, Phase 4 3, Phase 3 35, Phase 2/3 5, Phase 2 27, Phase 1/2 5, Phase 1 6) 2007: 148 trials (Observational 42, Not applicable 26, Phase 4 11, Phase 3 32, Phase 2/3 6, Phase 2 22, Phase 1/2 3, Phase 1 6) 2008: 147 trials (Observational 35, Not applicable 31, Phase 4 17, Phase 3 29, Phase 2/3 5, Phase 2 20, Phase 1/2 6, Phase 1 4) 2009: 165 trials (Observational 53, Not applicable 37, Phase 4 11, Phase 3 28, Phase 2/3 3, Phase 2 15, Phase 1/2 7, Phase 1 11) 2010: 170 trials (Other 1, Observational 51, Not applicable 33, Phase 4 14, Phase 3 14, Phase 2/3 1, Phase 2 28, Phase 1/2 11, Phase 1 17) 2011: 177 trials (Observational 67, Not applicable 21, Phase 4 16, Phase 3 22, Phase 2/3 3, Phase 2 29, Phase 1/2 5, Phase 1 14) 2012: 215 trials (Observational 65, Not applicable 51, Phase 4 15, Phase 3 26, Phase 2/3 1, Phase 2 36, Phase 1/2 7, Phase 1 14) 2013: 200 trials (Observational 57, Not applicable 55, Phase 4 17, Phase 3 13, Phase 2/3 3, Phase 2 29, Phase 1/2 7, Phase 1 19) 2014: 267 trials (Observational 84, Not applicable 68, Phase 4 23, Phase 3 29, Phase 2/3 6, Phase 2 30, Phase 1/2 7, Phase 1 20) 2015: 266 trials (Observational 91, Not applicable 68, Phase 4 23, Phase 3 23, Phase 2/3 4, Phase 2 26, Phase 1/2 11, Phase 1 20) 2016: 269 trials (Observational 82, Not applicable 78, Phase 4 29, Phase 3 22, Phase 2/3 4, Phase 2 30, Phase 1/2 5, Phase 1 19) 2017: 293 trials (Observational 99, Not applicable 91, Phase 4 20, Phase 3 21, Phase 2/3 4, Phase 2 28, Phase 1/2 9, Phase 1 21) 2018: 283 trials (Observational 89, Not applicable 80, Phase 4 18, Phase 3 31, Phase 2/3 8, Phase 2 37, Phase 1/2 3, Phase 1 17) 2019: 293 trials (Observational 106, Not applicable 88, Phase 4 21, Phase 3 13, Phase 2/3 8, Phase 2 31, Phase 1/2 8, Phase 1 18) 2020: 302 trials (Observational 120, Not applicable 81, Phase 4 12, Phase 3 22, Phase 2/3 5, Phase 2 31, Phase 1/2 6, Phase 1 25) 2021: 330 trials (Observational 118, Not applicable 91, Phase 4 19, Phase 3 33, Phase 2/3 3, Phase 2 38, Phase 1/2 4, Phase 1 24) 2022: 316 trials (Observational 114, Not applicable 96, Phase 4 20, Phase 3 15, Phase 2/3 6, Phase 2 32, Phase 1/2 8, Phase 1 25) 2023: 333 trials (Observational 119, Not applicable 102, Phase 4 19, Phase 3 20, Phase 2/3 7, Phase 2 37, Phase 1/2 7, Phase 1 22) 2024: 329 trials (Observational 121, Not applicable 105, Phase 4 17, Phase 3 20, Phase 2/3 3, Phase 2 32, Phase 1/2 8, Phase 1 23) 2025: 352 trials (Observational 135, Not applicable 112, Phase 4 18, Phase 3 21, Phase 2/3 2, Phase 2 38, Phase 1/2 5, Phase 1 21)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 303
2025 352
2024 329
2023 333
2022 316
2021 330
2020 302
2019 293
2018 283
2017 293

Showing 10 of 36 earlier years.

Start your 14-day trial Email me all 36 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 350 trials starting in 2026 and about 350 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 472 trials still running at the 2026-10-09 snapshot; registered median of 25 months across 3,326 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Gastroenteritis trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 399
Phase 1/2 148
Phase 2 714
Phase 2/3 103
Phase 3 572
Phase 4 406
Not applicable 1,478
Observational 1,848
Expanded access 10
Unknown 1

How many Gastroenteritis trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 276
Recruiting 704
Enrolling by invitation 48
Active, not recruiting 209
Available 4

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Gastroenteritis trials? (8)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Takeda 96
AbbVie 74
Pfizer 60
GlaxoSmithKline 57
Janssen Research & Development, LLC 46

Showing 5 of 8 sponsors.

Start your 14-day trial Email me all 8 sponsors as a PDF

Which drugs are being tested for Gastroenteritis? (2)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
INFLIXIMAB 116
Certolizumab 31

Interventions as named in the registry (13)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Vedolizumab IV 89
Adalimumab-US 86
MMX Mesalamine 82
Ustekinumab SC 54
Fecal Microbiota Transplantation 49

Showing 5 of 13 interventions.

Start your 14-day trial Email me all 13 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Gastroenteritis trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Crohn's disease 2,590 113
CROHN'S DISEASE 1,569 29
Colitis ulcerative 1,546 129
Pneumonia 789 127
Colitis Ulcerative 742 20

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Gastroenteritis? (324)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Retrospective Description of 27 Cases of Nontyphoidal Salmonella Meningitis in Pediatrics Over 22 Years in France Pleads for a Revision of Age Limit for the Treatment of Salmonella Gastroenteritis in Children. The Pediatric infectious disease journal 2026 Yes
Safety, immunogenicity, and relative efficacy of a parenteral trivalent rotavirus subunit vaccine candidate (TV P2-VP8) in healthy Ghanaian, Malawian, and Zambian infants. Vaccine 2026 Yes
A randomised trial of pleuran in paediatric acute gastroenteritis. Scientific reports 2025 Yes
Plasmalyte versus saline solution for rapid rehydration in gastroenteritis: prospective observational study. Anales de pediatria 2025 Yes
Multidose Ondansetron after Emergency Visits in Children with Gastroenteritis. The New England journal of medicine 2025 Yes

Showing 5 of 324 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (11)

MeSH descendants one level down with at least one trial, most trials first.

+1 more sub-condition

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages